Tvardi Therapeutics（TVRD）株式概要Tvardi Therapeutics, Inc.は臨床段階にあるバイオ医薬品会社で、米国でアンメットニーズの高い炎症性・増殖性疾患を治療するため、シグナル変換・転写活性化因子3（STAT3）を標的とした新規の経口・低分子治療薬の開発に取り組んでいる。 詳細TVRD ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析今後3年間の収益は年平均19.4%減少すると予測されている。 収益が 100 万ドル未満 ( $0 )現在は利益が出ておらず、今後3年間で利益が出る見込みはない 意味のある時価総額がありません ( $33M )すべてのリスクチェックを見るTVRD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$3.44該当なし内在価値ディスカウントEst. Revenue$PastFuture-35m182016201920222025202620282031Revenue US$18.0Earnings US$2.7AdvancedSet Fair ValueView all narrativesTvardi Therapeutics, Inc. 競合他社Nasus PharmaSymbol: NYSEAM:NSRXMarket cap: US$34.0mGrace TherapeuticsSymbol: NasdaqCM:GRCEMarket cap: US$34.0mQ/C TechnologiesSymbol: NasdaqCM:QCLSMarket cap: US$32.8mDaré BioscienceSymbol: NasdaqCM:DAREMarket cap: US$35.5m価格と性能株価の高値、安値、推移の概要Tvardi Therapeutics過去の株価現在の株価US$3.4452週高値US$43.6552週安値US$2.75ベータ01ヶ月の変化10.97%3ヶ月変化-10.65%1年変化-89.70%3年間の変化n/a5年間の変化n/aIPOからの変化-81.15%最新ニュースお知らせ • May 03Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Mar 09Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026.分析記事 • Jan 29Is Tvardi Therapeutics (NASDAQ:TVRD) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • Jan 08Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsTvardi Therapeutics, Inc. provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF), with preliminary results previously announced on October 13, 2025. Additional analysis was conducted to assess the impact of STAT3 inhibition using TTI-101 on fibrosis, inflammatory markers and pulmonary function, and this analysis was limited to patients who were exposed to the study drug for 12 weeks. Following review of pharmacokinetics and adverse events, one patient was removed from the analysis due to receiving less than 60% of the expected dosing, two patients were removed due to no measurable TTI-101 observed in the blood and no reported adverse events, and one additional patient was removed as an outlier because pulmonary function initially improved on treatment but was later severely impacted by acute bronchitis deemed unrelated to the study drug. This resulted in a dataset of 40 patients analyzed, including 16 pooled patients treated with TTI-101 and 24 patients treated with placebo. Data highlights showed that fibrosis decline was greater in patients treated with TTI-101 compared to placebo, at -9.4% versus -2.4%, respectively, based on baseline-weighted high resolution CT lung fibrosis scores that were centrally read, blinded and independently assessed. In terms of inflammation, a greater decline in IL-6 was observed among TTI-101-treated patients compared to placebo, with an even greater reduction seen in patients with higher baseline IL-6 levels; IL-6 is a key pro-inflammatory cytokine that signals through STAT3, and inhibition of STAT3 is expected to reduce downstream inflammatory signaling associated with disease. Additionally, 63% of pooled patients treated with TTI-101 demonstrated an increase in forced vital capacity (FVC) at 12 weeks compared to 46% of patients in the placebo group, and the mean FVC change in TTI-101-treated patients was -15 mL, representing a smaller decline than observed in the REVERT placebo group (-22 mL) and historical placebo groups from comparable IPF trials. The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study of TTI-101 alone or in combination with nintedanib (OFEV®) in patients with IPF, designed to assess safety, pharmacokinetics and exploratory outcomes related to lung function, and Tvardi announced on October 13, 2025 that the study did not meet its goals after reviewing preliminary safety data and efficacy results.お知らせ • Oct 14Tvardi Therapeutics, Inc. Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 alone or in addition to nintedanib (OFEV) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Overall, 88 patients were randomized to TTI-101 400mg per day (n=30), 800mg per day (n=29) or placebo (n=29), and stratified by nintedanib use, with 58% of patients receiving concomitant therapy. Preliminary data demonstrated patients' baseline characteristics were similar across treatment arms, with the exception of% predicted FVC, which was lower in the placebo-treated patients (70.1%) compared to the TTI-101-treated arms (74.1% and 81.1%, respectively). Discontinuation rates across treatment arms were imbalanced, with lower discontinuation rates observed in the placebo group (10.3%) compared to treated arms (400mg and 800mg; 56.7% vs 62.1%, respectively). Disconuation rates among the TTI-101 population were primarily driven by gastrointestinal adverse events, with higher rates of events and discontinuations among patients on concurrent nintedanib. The study was not powered to evaluate exploratory endpoints. The number of efficacy evaluable patients with at least one baseline and on-treatment FVC measurement was placebo (n=29), 400mg (n=23), and 800mg (n=27). The numbers, however, declined by the 12-week timepoint to placebo (n=24), 400mg (n=8), or 800mg (n=13). The preliminary analysis was performed on actual FVC values; values were not modeled or imputed. Preliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms. Overall, from baseline to last visit on treatment, the proportion of patients who demonstrated FVC improvement from baseline was 41% for the placebo, and 39% and 44% for the 400mg and 800mg arms, respectively. FVC change from baseline overlapped between treatment arms, with large variability within each cohort. Notably, the placebo-treated patients' FVC decline was lower than expected compared to historical controls.New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings are forecast to decline by an average of 46% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$146m net loss in 3 years).最新情報をもっと見るRecent updatesお知らせ • May 03Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Mar 09Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026.分析記事 • Jan 29Is Tvardi Therapeutics (NASDAQ:TVRD) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • Jan 08Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsTvardi Therapeutics, Inc. provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF), with preliminary results previously announced on October 13, 2025. Additional analysis was conducted to assess the impact of STAT3 inhibition using TTI-101 on fibrosis, inflammatory markers and pulmonary function, and this analysis was limited to patients who were exposed to the study drug for 12 weeks. Following review of pharmacokinetics and adverse events, one patient was removed from the analysis due to receiving less than 60% of the expected dosing, two patients were removed due to no measurable TTI-101 observed in the blood and no reported adverse events, and one additional patient was removed as an outlier because pulmonary function initially improved on treatment but was later severely impacted by acute bronchitis deemed unrelated to the study drug. This resulted in a dataset of 40 patients analyzed, including 16 pooled patients treated with TTI-101 and 24 patients treated with placebo. Data highlights showed that fibrosis decline was greater in patients treated with TTI-101 compared to placebo, at -9.4% versus -2.4%, respectively, based on baseline-weighted high resolution CT lung fibrosis scores that were centrally read, blinded and independently assessed. In terms of inflammation, a greater decline in IL-6 was observed among TTI-101-treated patients compared to placebo, with an even greater reduction seen in patients with higher baseline IL-6 levels; IL-6 is a key pro-inflammatory cytokine that signals through STAT3, and inhibition of STAT3 is expected to reduce downstream inflammatory signaling associated with disease. Additionally, 63% of pooled patients treated with TTI-101 demonstrated an increase in forced vital capacity (FVC) at 12 weeks compared to 46% of patients in the placebo group, and the mean FVC change in TTI-101-treated patients was -15 mL, representing a smaller decline than observed in the REVERT placebo group (-22 mL) and historical placebo groups from comparable IPF trials. The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study of TTI-101 alone or in combination with nintedanib (OFEV®) in patients with IPF, designed to assess safety, pharmacokinetics and exploratory outcomes related to lung function, and Tvardi announced on October 13, 2025 that the study did not meet its goals after reviewing preliminary safety data and efficacy results.お知らせ • Oct 14Tvardi Therapeutics, Inc. Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 alone or in addition to nintedanib (OFEV) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Overall, 88 patients were randomized to TTI-101 400mg per day (n=30), 800mg per day (n=29) or placebo (n=29), and stratified by nintedanib use, with 58% of patients receiving concomitant therapy. Preliminary data demonstrated patients' baseline characteristics were similar across treatment arms, with the exception of% predicted FVC, which was lower in the placebo-treated patients (70.1%) compared to the TTI-101-treated arms (74.1% and 81.1%, respectively). Discontinuation rates across treatment arms were imbalanced, with lower discontinuation rates observed in the placebo group (10.3%) compared to treated arms (400mg and 800mg; 56.7% vs 62.1%, respectively). Disconuation rates among the TTI-101 population were primarily driven by gastrointestinal adverse events, with higher rates of events and discontinuations among patients on concurrent nintedanib. The study was not powered to evaluate exploratory endpoints. The number of efficacy evaluable patients with at least one baseline and on-treatment FVC measurement was placebo (n=29), 400mg (n=23), and 800mg (n=27). The numbers, however, declined by the 12-week timepoint to placebo (n=24), 400mg (n=8), or 800mg (n=13). The preliminary analysis was performed on actual FVC values; values were not modeled or imputed. Preliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms. Overall, from baseline to last visit on treatment, the proportion of patients who demonstrated FVC improvement from baseline was 41% for the placebo, and 39% and 44% for the 400mg and 800mg arms, respectively. FVC change from baseline overlapped between treatment arms, with large variability within each cohort. Notably, the placebo-treated patients' FVC decline was lower than expected compared to historical controls.New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings are forecast to decline by an average of 46% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$146m net loss in 3 years).お知らせ • May 27Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). TTI-101, is an oral, small molecule inhibitor of STAT3. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. Tvardi-101 has demonstrated a unique and powerful dual mechanism of action: inhibiting STAT3-driven proliferation while activating T-cells, resulting in reduced lung fibrosis and restored lung function in preclinical studies.Board Change • Apr 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Shaheen Wirk was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元TVRDUS PharmaceuticalsUS 市場7D-7.3%2.6%2.5%1Y-89.7%41.5%26.4%株主還元を見る業界別リターン: TVRD過去 1 年間で41.5 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: TVRDは、過去 1 年間で26.4 % のリターンを上げたUS市場を下回りました。価格変動Is TVRD's price volatile compared to industry and market?TVRD volatilityTVRD Average Weekly Movement10.6%Pharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: TVRD 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: TVRDの 週次ボラティリティ は、過去 1 年間で16%から11%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト201712Imran Alibhaitvarditherapeutics.comTvardi Therapeutics, Inc.は、臨床段階にあるバイオ医薬品企業で、米国でアンメットニーズの高い炎症性・増殖性疾患を治療するため、シグナル伝達物質・転写活性化因子3（STAT3）を標的とした新規の経口・低分子治療薬の開発に取り組んでいる。同社の主要製品候補には、特発性肺線維症（IPF）および肝細胞癌（HCC）に初期焦点を当てた線維症主導型疾患を対象とした臨床開発段階（フェーズ1b/2）にあるTTI-101、および臨床試験段階（フェーズ1）にある経口低分子STAT3阻害剤TTI-109が含まれる。Tvardi Therapeutics, Inc.は2017年に設立され、テキサス州シュガーランドを拠点としている。もっと見るTvardi Therapeutics, Inc. 基礎のまとめTvardi Therapeutics の収益と売上を時価総額と比較するとどうか。TVRD 基礎統計学時価総額US$33.49m収益（TTM）-US$15.44m売上高(TTM)n/a0.0xP/Sレシオ-2.1xPER（株価収益率TVRD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計TVRD 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$15.44m収益-US$15.44m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.65グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%TVRD の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 14:42終値2026/05/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Tvardi Therapeutics, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Etzer DaroutBarclaysJulian HarrisonBTIGSteven SeedhouseCantor Fitzgerald & Co.5 その他のアナリストを表示
お知らせ • May 03Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Mar 09Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026.
分析記事 • Jan 29Is Tvardi Therapeutics (NASDAQ:TVRD) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • Jan 08Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsTvardi Therapeutics, Inc. provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF), with preliminary results previously announced on October 13, 2025. Additional analysis was conducted to assess the impact of STAT3 inhibition using TTI-101 on fibrosis, inflammatory markers and pulmonary function, and this analysis was limited to patients who were exposed to the study drug for 12 weeks. Following review of pharmacokinetics and adverse events, one patient was removed from the analysis due to receiving less than 60% of the expected dosing, two patients were removed due to no measurable TTI-101 observed in the blood and no reported adverse events, and one additional patient was removed as an outlier because pulmonary function initially improved on treatment but was later severely impacted by acute bronchitis deemed unrelated to the study drug. This resulted in a dataset of 40 patients analyzed, including 16 pooled patients treated with TTI-101 and 24 patients treated with placebo. Data highlights showed that fibrosis decline was greater in patients treated with TTI-101 compared to placebo, at -9.4% versus -2.4%, respectively, based on baseline-weighted high resolution CT lung fibrosis scores that were centrally read, blinded and independently assessed. In terms of inflammation, a greater decline in IL-6 was observed among TTI-101-treated patients compared to placebo, with an even greater reduction seen in patients with higher baseline IL-6 levels; IL-6 is a key pro-inflammatory cytokine that signals through STAT3, and inhibition of STAT3 is expected to reduce downstream inflammatory signaling associated with disease. Additionally, 63% of pooled patients treated with TTI-101 demonstrated an increase in forced vital capacity (FVC) at 12 weeks compared to 46% of patients in the placebo group, and the mean FVC change in TTI-101-treated patients was -15 mL, representing a smaller decline than observed in the REVERT placebo group (-22 mL) and historical placebo groups from comparable IPF trials. The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study of TTI-101 alone or in combination with nintedanib (OFEV®) in patients with IPF, designed to assess safety, pharmacokinetics and exploratory outcomes related to lung function, and Tvardi announced on October 13, 2025 that the study did not meet its goals after reviewing preliminary safety data and efficacy results.
お知らせ • Oct 14Tvardi Therapeutics, Inc. Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 alone or in addition to nintedanib (OFEV) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Overall, 88 patients were randomized to TTI-101 400mg per day (n=30), 800mg per day (n=29) or placebo (n=29), and stratified by nintedanib use, with 58% of patients receiving concomitant therapy. Preliminary data demonstrated patients' baseline characteristics were similar across treatment arms, with the exception of% predicted FVC, which was lower in the placebo-treated patients (70.1%) compared to the TTI-101-treated arms (74.1% and 81.1%, respectively). Discontinuation rates across treatment arms were imbalanced, with lower discontinuation rates observed in the placebo group (10.3%) compared to treated arms (400mg and 800mg; 56.7% vs 62.1%, respectively). Disconuation rates among the TTI-101 population were primarily driven by gastrointestinal adverse events, with higher rates of events and discontinuations among patients on concurrent nintedanib. The study was not powered to evaluate exploratory endpoints. The number of efficacy evaluable patients with at least one baseline and on-treatment FVC measurement was placebo (n=29), 400mg (n=23), and 800mg (n=27). The numbers, however, declined by the 12-week timepoint to placebo (n=24), 400mg (n=8), or 800mg (n=13). The preliminary analysis was performed on actual FVC values; values were not modeled or imputed. Preliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms. Overall, from baseline to last visit on treatment, the proportion of patients who demonstrated FVC improvement from baseline was 41% for the placebo, and 39% and 44% for the 400mg and 800mg arms, respectively. FVC change from baseline overlapped between treatment arms, with large variability within each cohort. Notably, the placebo-treated patients' FVC decline was lower than expected compared to historical controls.
New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings are forecast to decline by an average of 46% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$146m net loss in 3 years).
お知らせ • May 03Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.Tvardi Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Mar 09Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026Tvardi Therapeutics, Inc., Annual General Meeting, Jun 09, 2026.
分析記事 • Jan 29Is Tvardi Therapeutics (NASDAQ:TVRD) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • Jan 08Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical InsightsTvardi Therapeutics, Inc. provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF), with preliminary results previously announced on October 13, 2025. Additional analysis was conducted to assess the impact of STAT3 inhibition using TTI-101 on fibrosis, inflammatory markers and pulmonary function, and this analysis was limited to patients who were exposed to the study drug for 12 weeks. Following review of pharmacokinetics and adverse events, one patient was removed from the analysis due to receiving less than 60% of the expected dosing, two patients were removed due to no measurable TTI-101 observed in the blood and no reported adverse events, and one additional patient was removed as an outlier because pulmonary function initially improved on treatment but was later severely impacted by acute bronchitis deemed unrelated to the study drug. This resulted in a dataset of 40 patients analyzed, including 16 pooled patients treated with TTI-101 and 24 patients treated with placebo. Data highlights showed that fibrosis decline was greater in patients treated with TTI-101 compared to placebo, at -9.4% versus -2.4%, respectively, based on baseline-weighted high resolution CT lung fibrosis scores that were centrally read, blinded and independently assessed. In terms of inflammation, a greater decline in IL-6 was observed among TTI-101-treated patients compared to placebo, with an even greater reduction seen in patients with higher baseline IL-6 levels; IL-6 is a key pro-inflammatory cytokine that signals through STAT3, and inhibition of STAT3 is expected to reduce downstream inflammatory signaling associated with disease. Additionally, 63% of pooled patients treated with TTI-101 demonstrated an increase in forced vital capacity (FVC) at 12 weeks compared to 46% of patients in the placebo group, and the mean FVC change in TTI-101-treated patients was -15 mL, representing a smaller decline than observed in the REVERT placebo group (-22 mL) and historical placebo groups from comparable IPF trials. The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study of TTI-101 alone or in combination with nintedanib (OFEV®) in patients with IPF, designed to assess safety, pharmacokinetics and exploratory outcomes related to lung function, and Tvardi announced on October 13, 2025 that the study did not meet its goals after reviewing preliminary safety data and efficacy results.
お知らせ • Oct 14Tvardi Therapeutics, Inc. Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 alone or in addition to nintedanib (OFEV) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Overall, 88 patients were randomized to TTI-101 400mg per day (n=30), 800mg per day (n=29) or placebo (n=29), and stratified by nintedanib use, with 58% of patients receiving concomitant therapy. Preliminary data demonstrated patients' baseline characteristics were similar across treatment arms, with the exception of% predicted FVC, which was lower in the placebo-treated patients (70.1%) compared to the TTI-101-treated arms (74.1% and 81.1%, respectively). Discontinuation rates across treatment arms were imbalanced, with lower discontinuation rates observed in the placebo group (10.3%) compared to treated arms (400mg and 800mg; 56.7% vs 62.1%, respectively). Disconuation rates among the TTI-101 population were primarily driven by gastrointestinal adverse events, with higher rates of events and discontinuations among patients on concurrent nintedanib. The study was not powered to evaluate exploratory endpoints. The number of efficacy evaluable patients with at least one baseline and on-treatment FVC measurement was placebo (n=29), 400mg (n=23), and 800mg (n=27). The numbers, however, declined by the 12-week timepoint to placebo (n=24), 400mg (n=8), or 800mg (n=13). The preliminary analysis was performed on actual FVC values; values were not modeled or imputed. Preliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms. Overall, from baseline to last visit on treatment, the proportion of patients who demonstrated FVC improvement from baseline was 41% for the placebo, and 39% and 44% for the 400mg and 800mg arms, respectively. FVC change from baseline overlapped between treatment arms, with large variability within each cohort. Notably, the placebo-treated patients' FVC decline was lower than expected compared to historical controls.
New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings are forecast to decline by an average of 46% per year for the foreseeable future. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$146m net loss in 3 years).
お知らせ • May 27Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary FibrosisTvardi Therapeutics, Inc. announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI- 101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). TTI-101, is an oral, small molecule inhibitor of STAT3. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. Tvardi-101 has demonstrated a unique and powerful dual mechanism of action: inhibiting STAT3-driven proliferation while activating T-cells, resulting in reduced lung fibrosis and restored lung function in preclinical studies.
Board Change • Apr 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Shaheen Wirk was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
